Suppr超能文献

微粒体前列腺素 E 合酶 2 缺乏对乙酰氨基酚诱导的肝损伤有抵抗力。

Microsomal prostaglandin E synthase 2 deficiency is resistant to acetaminophen-induced liver injury.

机构信息

Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, 221004, Jiangsu, People's Republic of China.

Changshu NO. 2, People's Hospital, Suzhou, 215500, Jiangsu, People's Republic of China.

出版信息

Arch Toxicol. 2019 Oct;93(10):2863-2878. doi: 10.1007/s00204-019-02543-1. Epub 2019 Aug 23.

Abstract

Acetaminophen (APAP)-induced liver injury is the main cause of acute liver failure. This study investigated the role of microsomal prostaglandin E synthase 2 (mPGES-2), discovered as one of the prostaglandin E2 (PGE2) synthases, in mediating APAP-induced liver injury. Using mPGES-2 wild-type (WT) and knockout (KO) mice, marked resistance to APAP-induced liver damage was found in mPGES-2 KO, as indicated by robust improvement of liver histology, changes in liver enzyme release, and marked decrease in APAP-cysteine adducts (APAP-CYS) and inflammatory markers. Moreover, the results confirmed that increase in liver PGE2 content in KO mice under basal conditions was not critical for the protection from APAP-induced liver injury. Importantly, mPGES-2 deletion inhibited the production of malondialdehyde (MDA), increasing glutathione (GSH) level. Enhanced GSH level may contribute to the inhibition of APAP toxicity in mPGES-2 KO mice. To further elucidate the role of mPGES-2 in the liver injury induced by APAP, adeno-associated viruses (AAV) were used to overexpress mPGES-2 in the liver. The results showed that mPGES-2 overexpression aggravates liver injury associated with an increase in inflammatory markers and chemokines after APAP treatment. Moreover, a lower level of GSH was detected in the mPGES-2 overexpression group compared to the control group. Collectively, our findings indicate that mPGES-2 plays a critical role in regulating APAP-induced liver injury, possibly by regulating GSH and APAP-CYS level, which may provide a potential therapeutic strategy for the prevention and treatment of APAP-induced liver injury.

摘要

对乙酰氨基酚(APAP)诱导的肝损伤是急性肝衰竭的主要原因。本研究探讨了微粒体前列腺素 E 合酶 2(mPGES-2)在介导 APAP 诱导的肝损伤中的作用,该酶是前列腺素 E2(PGE2)合酶之一。使用 mPGES-2 野生型(WT)和敲除(KO)小鼠,发现 mPGES-2 KO 对 APAP 诱导的肝损伤具有明显的抗性,表现为肝组织学明显改善、肝酶释放变化以及 APAP-半胱氨酸加合物(APAP-CYS)和炎症标志物明显减少。此外,结果证实,KO 小鼠基础状态下肝 PGE2 含量的增加对于保护免受 APAP 诱导的肝损伤并不关键。重要的是,mPGES-2 缺失抑制了丙二醛(MDA)的产生,增加了谷胱甘肽(GSH)水平。增强的 GSH 水平可能有助于抑制 mPGES-2 KO 小鼠中的 APAP 毒性。为了进一步阐明 mPGES-2 在 APAP 诱导的肝损伤中的作用,使用腺相关病毒(AAV)在肝脏中过表达 mPGES-2。结果表明,mPGES-2 的过表达加重了与 APAP 处理后炎症标志物和趋化因子增加相关的肝损伤。此外,与对照组相比,mPGES-2 过表达组的 GSH 水平较低。总的来说,我们的研究结果表明,mPGES-2 在调节 APAP 诱导的肝损伤中起着关键作用,可能通过调节 GSH 和 APAP-CYS 水平来实现,这可能为预防和治疗 APAP 诱导的肝损伤提供一种潜在的治疗策略。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验